Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Hematologic Malignancies
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1480880
This article is part of the Research Topic Elderly Patients and Lymphoma View all 4 articles

Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: A case report and literature review

Provisionally accepted
Wang Hongxia Wang Hongxia Bai junjun Bai junjun *Song Qinglin Song Qinglin *
  • The People's Hospital of Jiaozuo City, Jiaozuo, China

The final, formatted version of the article will be published soon.

    We report a case of a 53-year-old male patient who was diagnosed with anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma (LBCL). Pathological examination showed plasma-cell immunophenotype negative for mature B-lymphocyte markers. The patient received three cycles of "alectinib + VRCD" regimen. In the fourth cycle, BV monoclonal antibody was added to increase efficacy. PET-CT and bone marrow examination were carried out after four cycles, revealing complete response (CR). Stem cells were successfully harvested.So far, the patient has undergone six treatment cycles and successfully received autologous hematopoietic stem cell transplantation. Currently, the patient is receiving maintenance therapy with alectinib and lenalidomide and remains in a favorable clinical condition.

    Keywords: ALK+ LBCL, Aletinib, Bortezomib, Lenalidomide, BV monoclonal antibody

    Received: 14 Aug 2024; Accepted: 19 Dec 2024.

    Copyright: © 2024 Hongxia, junjun and Qinglin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Bai junjun, The People's Hospital of Jiaozuo City, Jiaozuo, China
    Song Qinglin, The People's Hospital of Jiaozuo City, Jiaozuo, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.